23 November, 2023 | Online
Chairs: Prof. Dr Christoph Lange (Borstel, Germany); Prof. Dr Raquel Duarte (Porto, Portugal)
Speakers: Dr. Elin Svensson (Uppsala, Sweden)
Discussants: Dr. Andrii Dudnyk (Vinnytsia, Ukraine), Dr. Wandini Lutchmun (Munich, Germany)
To successfully treat tuberculosis it is an absolute necessity that the antimicrobial agents used reaches the site of infection in sufficient amounts. This is ensured by carefully selected doses, accounting for patient factors and potential interactions with co-administered compounds.
To understand the link between drug doses and treatment outcome, and the principal processes governing the relation.
The webinar will be divided into 2 parts:
UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active Tuberculosis (TB) treatment regimens for drug-resistant and -sensitive TB. For more information, visit the consortium website: www.unite4TB.org
The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: www.imi.europa.eu
This communication reflects the author's view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.